A trial update for exenatide was recorded on August 4, 2026. The study, registered as NCT05663515, is titled "A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs."
The study's current status is listed as recruiting. No phase designation was provided for this trial in the available record.
This is a post-authorisation safety study examining type 2 diabetes patients who initiated exenatide compared with those who initiated other non-GLP-1 receptor agonist glucose lowering drugs. The stated focus is on pancreatic cancer risk comparison between these treatment groups.
No results have been posted for this study as of the update date. The recruiting status indicates the study is still enrolling participants and has not reached a stage where outcome data would be available.
Readers should note that this update reflects only the trial's status as of the recorded date and does not include any findings, conclusions, or safety signals. Further updates may follow as the study progresses through recruitment and subsequent phases.
For more background on exenatide, including its approved uses and regulatory status, see the compound overview.